1. "Hematologic Malignancies Research"
Formats
  1. Journal Article (1521)
  2. Meeting Abstract (1232)
  3. Review (76)
  4. Editorial (34)
  5. Book Section (32)
  6. Research Letter (25)
  7. Conference Paper (15)
  8. Correspondence (7)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (2950)
  2. Hematologic Malignancies Research (2950)
  3. GSK Faculty (2412)
  4. Department of Medicine (2277)
  5. Hematologic Malignancies, Division of (2078)
  6. Sloan Kettering Institute Faculty (2026)

More Groups

People
  1. Michel Sadelain (582)
  2. David Scheinberg (499)
  3. Alexander Lesokhin (363)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (279)

More People

Years
  1. 2025 (32)
  2. 2024 (108)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (636)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (108)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (674)
  2. Nature Publishing Group (367)
  3. Elsevier Inc. (290)
  4. American Association for Cancer Research (245)
  5. Cell Press (116)
  6. American Society of Clinical Oncology (112)

More Publishers

Results (2950)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Biomarker correlates and clinical activity of cevostamab in patients (pts) with triple-class refractory multiple myeloma (MM) who have received ≥1 prior B-cell maturation antigen (BCMA)-targeted bispecific antibody (BsAb): Results from the phase I/II CAMMA 2 study
    Meeting Abstract

    Delforge, M.; Richter, J.; Cohen, Y. C.; Corradini, P.; Sborov, D. W.; Lesokhin, A. M.; Berdeja, J. G.; Gatt, M. E.; Paris, L.; Dachs, L. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • MagnetisMM-3: Long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Prince, H. M.; Bahlis, N. J.; Rodríguez-Otero, P.; Karlin, L.; Akard, L.; Varshavsky-Yanovsky, A.; Chu, M. P.; Nagai, Y.; Vesole, D. H.; Hickman, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Proteolytic control and therapeutic targeting of oncogenic gene expression in acute myeloid leukemia
    Meeting Abstract

    Uni, M.; Steinberg, A. P.; Slavit, A.; Rha, S.; Cheng, S.; Schmalbrock, L. K.; Su, J.; Ma, J.; McPherson, A.; Mullighan, C. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Targeting PERK arm of unfolded protein response helps to eliminate therapy-induced residual senescent-like acute myeloid leukemia cells
    Meeting Abstract

    Poigaialwar, G.; Takao, S.; Chaudhry, S.; Schmalbrock, L. K.; Gupta, V.; Kentsis, A.; Aguirre-Ghiso, J. A.; Konopleva, M.; Sosa, M. S.; Skwarska, A.
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • The histone acetyltransferase MOZ (KAT6A) is a molecular dependency and therapeutic target in NUP98-rearranged acute myeloid leukemia
    Meeting Abstract

    Michmerhuizen, N. L.; Heikamp, E.; Umeda, M.; Iacobucci, I.; Arthur, B.; Di Giacomo, D.; Hiltenbrand, R.; Radko-Juettner, S.; Portola, P.; Claquin, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-cell profiling aligns CD56bright and cytomegalovirus-induced adaptive natural killer cells to a naïve-memory relationship
    Journal Article

    Panjwani, M. K.; Grassmann, S.; Sottile, R.; Le Luduec, J. B.; Kontopoulos, T.; van der Ploeg, K.; Sun, J. C.; Hsu, K. C.
    Frontiers in Immunology (2024)

    Fulltext@MSK | Save
  • Interrogating the CD47-SIRP axis in chronic T cell stimulation for the translation of Graft-vs.-Host disease therapeutics
    Meeting Abstract

    Wallisch, P.; Bourne, C.; Pierre, S.; Kurtz, K.; Scheinberg, D.
    Journal of Immunology (2024)

    Fulltext@MSK | Save